1.

Introduction
Treatment guidelines for people with type 2 diabetes (T2DM) recommend the use of a variety of antihyperglycemic drugs after the failure of diet and lifestyle changes to help optimize glycemic control [1] [2] [3] . The sequence in which these drugs should be used is contentious, so treatment decisions should be made based on individual patient characteristics. Nevertheless, as T2DM progresses, prompt treatment intensification of these drugs, which includes the use of insulin, will be required. It is of concern that studies have identified a considerable potential delay (up to 7 years) when intensifying treatment [4] , as this, in turn, will impact upon the achievement of treatment goals and put poorly controlled patients at a high risk of diabetes-related complications [5] .
Although most patients with T2DM will eventually require treatment with insulin [6] , patients and physicians alike may be discouraged from starting this line of therapy due to concerns regarding the increased risk of hypoglycemia [7, 8] and potential weight gain [9] . Studies, however, have shown that starting basal insulin therapy in patients suboptimally controlled with oral antidiabetic drugs (OADs) may improve glycemic control with a low risk for hypoglycemia and weight gain [10, 11] . Notwithstanding the reported improvement in clinical outcomes, observational findings suggest that basal insulin dose in patients with T2DM could still be titrated further, thus indicating the potential for additional improvement in outcomes with dose escalation [11] . Once a patient is receiving basal insulin, there is a need to ensure that the treatment is monitored, titrated, and intensified in a timely and appropriate manner. Indeed, a recent UK study demonstrated that only 30.9% of patients who were receiving basal insulin and were eligible for treatment intensification (defined by HbA1c P 7.5% [P58.5 mmol/mol]) actually had their treatment intensified after a median 3.7-year delay; more concerning, 32.1% of patients stopped the use of basal insulin altogether [12] . Readily identifying patients who would benefit from more intensive titration or intensification (with postprandial glucose-controlling drugs) of their basal insulin regimen to prevent treatment inertia and/or withdrawal is an important challenge facing clinicians.
SOLVE was an international observational study conducted in 17,374 patients with T2DM inadequately controlled on OADs who were started on once-daily basal insulin with insulin detemir. After 24 weeks of treatment, 32.8% of patients achieved HbA1c < 7.0% (<53.0 mmol/mol) with a change in HbA1c from baseline (8.9%; 74 mmol/mol) of À1.3% (À14 mmol/mol; p < 0.001). Moreover, few adverse events, minor weight reduction, and low hypoglycemia rates were reported [11] . Based on SOLVE data, this post hoc analysis sets out to explore the characteristics of suboptimally controlled patients (defined as HbA1c P 7.0% at final visit) after basal insulin treatment, and therefore identify the characteristics of patients who are likely to benefit from intensive titration of basal insulin or further intensification.
2.
Materials and methods
SOLVE design
SOLVE methodology has been reported previously [11] . Briefly, SOLVE was a 24-week, observational, open-label study in patients with T2DM who were not achieving treatment targets with diet, exercise, and P1 OAD. Once-daily insulin detemir was added to each patient's existing therapy. The study was conducted at 2817 sites across 10 countries: Canada, China, Germany, Israel, Italy, Poland, Portugal, Spain, Turkey, and the UK. Baseline demographic data were collected for all patients who entered the study; this included any previous history of macro-or microvascular disease (defined elsewhere [11] ). In addition to baseline, data were collected at 12 and 24 weeks of treatment.
Post hoc analysis population and outcomes
All patients enrolled in SOLVE who were prescribed insulin detemir and included in the full analysis set (FAS) were considered for the analysis. Patients had to have information on HbA1c at the 12-week interim visit and at the 24-week final visit. Suboptimal glycemic control was defined as an HbA1c level P7.0% at final visit, as this is the threshold recommended for most patients by the American Diabetes Association and European Association for the Study of Diabetes [13] . Patients were divided into two groups based on whether they achieved HbA1c < 7.0% (<53 mmol/mol) or not at final visit. Supplementary analyses were conducted using an HbA1c cut-off of 7.5% (58.5 mmol/mol) and outcomes of both HbA1c cut-offs were investigated after 12 weeks of treatment.
The analysis explored the relationship between baseline patient characteristics and the attainment of HbA1c level P7.0% at 24 weeks. Baseline patient characteristics included demographics and indicators of disease severity. Clinical study outcomes recorded both at baseline and at the 24-week visit included glycemic control (HbA1c and fasting blood glucose [FBG] ), hypoglycemia, weight, and insulin dose. For the purpose of this analysis, the parameter 'any hypoglycemia' includes minor (daytime or nocturnal) and major episodes; these were combined, as there were only a few major episodes reported. An episode was considered minor if blood glucose was <3.1 mmol/l with or without symptoms (recalled within the last 4 weeks prior to visit). A major episode required third-party assistance with the administration of food, glucagon, or intravenous glucose (recalled within the last 12 weeks in all countries except the UK; the recall period in the UK was 4 weeks). Data on antihypertensive and/or lipid-lowering drugs were not collected in the study.
2.3.
Statistical analysis To account for mutual confounding, the association between selected exposure variables and HbA1c at 24 weeks was examined by multiple logistic regression (SAS enterprise guide 7.1, Cary, NC, USA). Wald estimates, 95% confidence interval (CI), and statistical significance were calculated by iterative maximum likelihood methods. Included variables were selected a priori based on prior knowledge of their association with HbA1c. Crude and adjusted results are presented. The main model was adjusted for country, HbA1c before insulin initiation, insulin dose at interim/final visit, sex, age, duration of diabetes, body mass index (BMI) before insulin initiation, microvascular complications, macrovascular complications, number of OADs before insulin initiation, duration of OAD treatment, change in number of OADs during study, any hypoglycemia during study, and any hypoglycemia before insulin initiation. FBG was not included in the main model, as there were too many missing values for this variable; instead, an identical model to the one described above, but with FBG included, was conducted separately to assess the association of FBG and HbA1c.
Results
Of the SOLVE population (n = 17,374), 10,763 patients had HbA1c information at the interim and final visits and therefore were included in the post hoc analysis. The excluded population were marginally younger (61.4 ± 11.7 years vs. 61.7 ± 11.4 years; p = 0.046), and had greater baseline HbA1c (9. ; p < 0.0001) compared with the analysis population. In addition, the excluded population presented a greater use of sulphonylureas (61.9% vs. 57.8%, p < 0.0001) and reduced use of glinides (14.7% vs. 16.9%, p < 0.0001) and a-glucosidase inhibitors (10.2% vs. 13.4%, p < 0.0001) compared with the analysis population.
After 24 weeks of basal insulin treatment, 66.3% (n = 7138) of the analysis population had an HbA1c level P 7.0% [P53.0 mmol/mol]).
Baseline characteristics
Based on a non-adjusted analysis of the pooled population, significantly different baseline characteristics in patients who had HbA1c P 7.0% (P53.0 mmol/mol) after 24 weeks included older age (p < 0.0001), longer duration of diabetes (p < 0.0001), higher weight (p < 0.0001), greater use of OADs (p < 0.0001; specifically biguanides, sulphonylureas, and aglucosidase inhibitors), and more frequent micro-and macrovascular complications (p < 0.0001 and p < 0.05, respectively) compared with patients who achieved HbA1c < 7.0% (Table 1) . Prevalence of HbA1c P 7.0% (P53.0 mmol/mol) at final visit was also related to country, with the highest prevalence of HbA1c P 7.0% in the UK (86.9%) and the lowest in China (49.7%). Similar trends in baseline characteristics were observed for individual countries (data not shown).
Association between baseline characteristics and suboptimal glycemic control
Crude and adjusted multiple logistic regression results are described in Table 2 . In the adjusted model, the baseline characteristics that remained significantly and independently associated with HbA1c P 7.0% (P53.0 mmol/mol) at final visit were duration of diabetes, number of OADs, and duration of OAD treatment. Gender, age, micro-and macrovascular complications (although borderline significant) were not independently associated with HbA1c P 7.0% (P53.0 mmol/mol).
Glycemic parameters
Patients with HbA1c P 7.0% (P53.0 mmol/mol) at final visit had significantly greater HbA1c and FBG levels at baseline and 24 weeks compared with patients achieving HbA1c target (Fig. 1) . After 24 weeks of treatment, patients with HbA1c P 7.0% (P53.0 mmol/mol) experienced a statistically significant reduction in HbA1c of À1.10 ± 1.5% (À12.0 ± 16.4 mmol/mol; p < 0.0001) from baseline, whereas patients with HbA1c < 7.0% had a reduction of À1.73 ± 1.5% (À18.9 ± 16.4 mmol/mol; p < 0.0001) from baseline. After 24 weeks of treatment, FBG was significantly reduced from baseline by À3.1 ± 3.1 mmol/l (À55.8 ± 55.8 mg/dl) in patients with HbA1c P 7.0% (53.0 mmol/mol) at final visit, and À3.2 ± 2.8 mmol/l (À57.6 ± 50.4 mg/dl) in patients with HbA1c < 7.0% (both p < 0.0001) at final visit. Final values were 7.7 ± 2.0 mmol/l (139 ± 36 mg/dl) and 6.3 ± 1.0 mmol/l (113 ± 18 mg/dl), respectively. In the adjusted regression model, HbA1c P 7.0% at final visit) was positively associated with the HbA1c level at baseline, but not with the FBG level at baseline (Table 2) .
Insulin dose
Insulin dose significantly increased by 0.12 ± 0.17 U/kg from baseline in patients with final HbA1c P 7.0 (53.0 mmol/mol) (p < 0.0001), and by 0.08 ± 0.13 U/kg in patients with final HbA1c < 7.0% (p < 0.0001). Final insulin dose values were significantly different from each other: 0.28 ± 0.17 U/kg (HbA1c P 7.0%) and 0.23 ± 0.14 U/kg (HbA1c < 7.0%) (p < 0.0001). In the adjusted regression model, HbA1c P 7.0% at final visit was positively associated with the insulin dose at 24 weeks (Table 2) .
Safety
After 24 weeks of treatment, the reporting of any hypoglycemia during the study was significantly less in patients with HbA1c P 7.0% (P53.0 mmol/mol) compared with patients with HbA1c < 7.0% at final visit (Fig. 2) . In terms of major hypoglycemia, 0.04% (n = 3) of patients with HbA1c P 7.0% (P53.0 mmol/mol) experienced an episode after 24 weeks compared with 0.19% (n = 7) of patients with HbA1c < 7.0% at final visit. The adjusted regression model supports the negative relationship between hypoglycemia during treatment and achieving HbA1c P 7.0% at 24 weeks (Table 2) . Mean weight and BMI were significantly greater at baseline in patients with HbA1c P 7.0% (P53.0 mmol/mol) at final visit compared with patients achieving HbA1c target (Table 1) . Body weight was significantly reduced by 0.4 ± 5.5 kg from baseline in patients with HbA1c P 7.0%, and by 0.9 ± 5.6 kg in patients with HbA1c < 7.0% (both p < 0.0001). In the adjusted model, HbA1c P 7.0% at final visit was positively associated with BMI at baseline ( Table 2 ).
Discussion
Patients with suboptimal glycemic control, defined as HbA1c P 7.0% (P53.0 mmol/mol) at final visit, were positively associated with baseline characteristics related to severity of disease; this included baseline HbA1c (the odds of not achieving glycemic target were 1.56 times greater for every 1.0% higher baseline HbA1c), duration of diabetes, BMI, number of OADs, and duration of OAD treatment. In contrast, suboptimal glycemic control was negatively associated with the reporting of hypoglycemia, i.e. more hypoglycemia was reported in patients who achieved glycemic target compared with those who did not. Suboptimally controlled patients also had a significantly higher insulin dose requirement after 24 weeks of treatment compared with patients with good glycemic control. These results support the findings of similar studies that have investigated predictors of glycemic control [14] [15] [16] . They all unequivocally demonstrate that baseline HbA1c is the strongest predictor associated with glycemic control. In a long-term 4-year study in patients with T2DM starting any insulin, suboptimal glycemic control was also associated with other baseline factors including BMI, age, diabetes duration, and use of OADs [14] . Balkau and colleagues also reported a strong association between high insulin dose and high HbA1c level. As in our study, this finding is rather unexpected, given that a higher insulin dose should reduce HbA1c and, indeed, HbA1c was reduced over the 24 weeks of the SOLVE study [11] . This finding is likely to be driven by reverse causation, i.e. high HbA1c caused the high insulin requirement, and not the other way around. Glycemic control varied across the participating countries, with the UK presenting the largest proportion of patients with HbA1c P 7.0% (86.9%) and China the lowest (49.7%). This difference is likely to be due to heterogeneity between the two populations prior to initiating the study. HbA1c level, insulin dose, population age, weight, and the incidence of macrovascular disease at baseline were all lower in the Chinese SOLVE population (data not shown); thus, with fewer comorbidities, the Chinese population may indeed be less insulin-resistant than the UK population. Furthermore, differences in OAD use may also contribute to the resulting glycemic profile; for example, the use of a-glucosidase inhibitors and glinides was more pronounced in the Chinese population compared with the UK population (data not shown). Although glycemic control was significantly improved in both groups of patients, there remains a need to further optimize the treatment of those patients who did not achieve glycemic target. At final visit, patients with HbA1c P 7.0% (P53.0 mmol/mol) had an FBG level of 7.7 mmol/l (138.6 mg/dl), which stands closely above the recommended FBG targets of 4.4-7.2 mmol/l (80-130 mg/dl) [2] or <6.1 mmol/l (110 mg/dl) [1] . In a randomized, treat-to-target, 20-week study in insulin-naïve patients with T2DM starting basal insulin therapy, Blonde and colleagues demonstrated that the majority of patients could achieve HbA1c < 7.0% (<53.0 mmol/mol) while titrating to an FBG target of 3.9-5.0 mmol/l (70.2-90 mg/dl) or 4.4-6.1 mmol/l (79.2-110 mg/dl) [10] . This was achieved while accompanied by low hypoglycemia rates. In our analysis, patients with suboptimal glycemic control also experienced significantly less hypoglycemia during the study compared with wellcontrolled patients, which suggests that their treatment could indeed be further titrated towards glycemic targets without adversely increasing the risk of hypoglycemia.
The above is also supported by the fact that, although insulin doses increased in both groups, the final dose in the suboptimally controlled group (0.28 U/kg) was relatively low compared with the insulin doses (0.4-0.6 U/kg) reported in randomized clinical trials that assessed the efficacy and safety of insulin detemir in insulin-naïve patients with T2DM [10, 17, 18] . This may not be that unexpected given that titration procedures in the SOLVE study were conducted at the investigators' discretion in routine clinical care. Furthermore, physicians may be more careful when titrating insulin in patients who present the features identified in the suboptimally controlled population (i.e. long duration of diabetes, high BMI, etc.) in order to reduce the risk of severe hypoglycemia and/or cardiovascular complications. Nevertheless, the findings of the analysis appear to support that, in some patients, there is a need for more aggressive titration towards recommended glycemic targets while being mindful of the risk of severe hypoglycemia. Treatment intensification with prandial insulin or other glucose-lowering drugs (e.g. glucagon-like peptide-1 receptor agonists [GLP-1RAs]) that target postprandial glucose could also be considered, particularly as final FBG levels were not far from the recommended target [13] ; however, American Diabetes Association guidelines only recommend this approach once the basal insulin dose is greater than 0.5 U/kg or if HbA1c remains uncontrolled despite achieving FBG target [13] . Given that neither of the above requirements strictly apply to our population, more intensive titration would appear to be the best initial option to help attain treatment goals.
Intensive treatment, particularly with insulin, can have an adverse effect on weight gain [19, 20] , and this may result in hesitation when further titration of basal insulin treatment is required. However, it should be noted that, in the SOLVE study, regardless of glycemic control, minor weight reduction was seen in both groups. Although extrinsic factors may play a role, the weight-sparing effect of insulin detemir could be attributed to a CNS-mediated reduction in energy intake [21] . Furthermore, randomized clinical trials have demonstrated a less adverse effect on weight gain with insulin detemir compared with other basal insulin, including NPH insulin [18] and insulin glargine [17] .
Other factors may hinder the intensification of basal insulin treatment, as demonstrated in a recent survey that assessed the perceptions on control and insulin intensification among physicians and patients with suboptimally controlled T2DM on basal insulin [22] . There was considerable reluctance by physicians to intensify treatment when an agreement could not be reached with the patient, while patients themselves were more concerned about weight gain and the perception of a worsening disease. A UK qualitative study also highlighted healthcare provider perceptions on clinical inertia, which identified patient factors (comorbidities and fallibility) and system-level factors (time constraints) as key contributors; however, the participants themselves seemed reluctant to accept a degree of responsibility for the inertia [23] . These factors are likely to be among several that contribute to the clinical inertia reported in patients on basal insulin. Remarkably, a UK retrospective analysis in T2DM showed that it took approximately 4 years to intensify patients' treatment following basal insulin, and this was conducted in only one-third of the patients who were actually eligible for intensification [12] . Duration of diabetes, older age, and OAD usage were significantly associated with the reported inertia in intensifying treatment [12] , factors that, based on our analysis, also appear to be associated with suboptimal glycemic control. Early identification of these factors in clinical practice is important to help physicians identify in a timely manner those patients likely to require modifications to their treatment.
In terms of strengths, our analysis had a large sample size and is fairly representative of primary and specialist care across 10 countries, and thus has relatively high external validity. Importantly, countries/regions may use different glycemic targets and, to account for this, we also conducted the analysis with an HbA1c cut-off of 7.5% (58.5 mmol/mol); this did not impact upon the findings (Supplementary Material). In addition, no differences were observed when conducting the analysis after 12 weeks of treatment (Supplementary Material); this was studied to help account for any potential differences in outcomes that may arise due to more active insulin titration typical of the first 3 months of treatment. Potential confounding was accounted for by multiple logistic regression, although this would not have been able to account for socioeconomic status and lifestyle factors. Limitations of the analysis include the possibility of reverse causation (as reported with insulin dose and HbA1c) and false-positive findings driven by multiple testing, although the data were consistently reported across countries. Of the overall SOLVE population, 38% of subjects were not eligible for this analysis due to missing data; it cannot be ruled out that inclusion of these data could influence the findings. There were many missing values for FBG, thus it was not included in the main adjusted model. Although some factors were statistically significant in the adjusted model (e.g. BMI, number of OADs), the odds ratios were very close to 1 and therefore the magnitude 
of change in these outcomes should be weighed against their clinical relevance. It should be highlighted that SOLVE was an observational study and, as such, any observed associations may not be causal; however, the observational nature of the study also helps reflect attitudes of real-world clinical practice.
In conclusion, we identified several baseline characteristics that were strongly associated with suboptimal glycemic control in patients with T2DM who were receiving oncedaily basal insulin. These factors may help clinicians in identifying patients who may require individualized titration or intensification of treatment. Indeed, in the suboptimally controlled group of the SOLVE population, insulin dose and the risk of hypoglycemia were relatively low, which, in combination with suboptimal FPG levels, suggests that a more aggressive titration regimen could be implemented to improve glycemic control while still maintaining a low risk of hypoglycemia. Alternatively, intensification of basal insulin treatment by adding postprandial glucose-lowering drugs like bolus insulin or GLP-1RAs can be considered in this patient group.
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